<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024128</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-028</org_study_id>
    <secondary_id>CDR0000068894</secondary_id>
    <nct_id>NCT00024128</nct_id>
  </id_info>
  <brief_title>Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma</brief_title>
  <official_title>Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <brief_summary>
    <textblock>
      RATIONALE: Donor peripheral stem cell transplantation may be able to replace immune cells&#xD;
      that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells&#xD;
      are rejected by the body's normal tissues. Treatment with donor white blood cells may prevent&#xD;
      this from happening.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell&#xD;
      transplantation followed by infusions of donor white blood cells in treating patients who&#xD;
      have AIDS-related lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate of patients with AIDS-related lymphoma treated with&#xD;
           allogeneic peripheral blood stem cell (PBSC) transplantation followed by delayed donor&#xD;
           leukocyte infusion.&#xD;
&#xD;
        -  Determine the complication rate of these patients treated with PBSC transplantation.&#xD;
&#xD;
        -  Determine the immune dysfunction and recovery of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive cyclophosphamide IV over 60 minutes on days -5 to -3. Patients who have not&#xD;
      received prior mediastinal radiotherapy receive thymic radiotherapy on day -1. Allogeneic&#xD;
      peripheral blood stem cells are infused on day 0. Patients also receive anti-thymocyte&#xD;
      globulin IV over 10-12 hours on days -1, 1, 3, and 5 and cyclosporine IV beginning on day -1,&#xD;
      switching to oral when possible, and tapering until day 35.&#xD;
&#xD;
      In the absence of active acute graft-versus-host disease (GVHD), and at least 2 weeks after&#xD;
      completion of cyclosporine, patients receive an infusion of donor leukocytes on or before day&#xD;
      49. Patients may receive a second donor leukocyte infusion if there is evidence of persistent&#xD;
      malignancy and no GVHD.&#xD;
&#xD;
      Patients are followed through day 100, on days 120, 180, 270, and 365, and then every 6&#xD;
      months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn prior to initiation.&#xD;
  </why_stopped>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Failed to achieve a complete remission with initial therapy OR&#xD;
&#xD;
               -  Relapsed after initial therapy&#xD;
&#xD;
          -  HIV-1 seropositive by Western Blot&#xD;
&#xD;
          -  Measurable or evaluable (e.g., pleural fluid involvement) disease&#xD;
&#xD;
          -  No leptomeningeal or parenchymal CNS involvement or active CNS leukemia&#xD;
&#xD;
          -  HLA-A, B, or DR antigen matched or 1 antigen mismatched related donor available&#xD;
&#xD;
          -  CD4 cell count greater than 100/mm3 (initial 12 patients) OR greater than 50/mm3&#xD;
             (subsequent patients)*&#xD;
&#xD;
          -  HIV RNA less than 110,000 copies/mL* NOTE: *Unless not receiving optimal&#xD;
             anti-retroviral therapy as defined by current clinical standards&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Physiologic 65 and under&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Estimated disease-free survival less than 1 year&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  SGOT or SGPT no greater than 3 times ULN*&#xD;
&#xD;
          -  Hepatitis B surface antigen negative NOTE: *Unless receiving indinavir&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  LVEF at least 45% by radionuclide ventriculography&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No severe chronic obstructive lung disease&#xD;
&#xD;
          -  No symptomatic restrictive lung disease&#xD;
&#xD;
          -  DLCO greater than 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No history of cytomegalovirus retinitis or pneumonitis, even if treated&#xD;
&#xD;
          -  No other disease that would limit life expectancy&#xD;
&#xD;
          -  No symptomatic leukoencephalopathy&#xD;
&#xD;
          -  No neuropsychiatric abnormalities that would preclude transplantation&#xD;
&#xD;
          -  Human T-cell lymphotrophic virus (HTLV-1) antibody negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 1 week since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent chronic suppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Scadden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>October 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2003</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>HIV-associated Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

